Vol. 2 No. 6 (2022): June
Reimbursement Reviews

Lorlatinib (Lorbrena)

Published June 3, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Lorlatinib (Lorbrena), 25 mg and 100 mg tablets, orally.
  • Indication: As monotherapy for the first-line treatment of adult patients with ALK-positive locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC).